Conclusion
Mesdopetam was safe and well tolerated in healthy male volunteers.
Pharmacokinetic analysis indicated rapid absorption and dose-linear
pharmacokinetics of mesdopetam, with a plasma half-life around 7 hours,
upon single and repeated dosing. The pharmacokinetics of mesdopetam
supports twice daily use in patients.